MX2022009059A - Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a. - Google Patents
Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a.Info
- Publication number
- MX2022009059A MX2022009059A MX2022009059A MX2022009059A MX2022009059A MX 2022009059 A MX2022009059 A MX 2022009059A MX 2022009059 A MX2022009059 A MX 2022009059A MX 2022009059 A MX2022009059 A MX 2022009059A MX 2022009059 A MX2022009059 A MX 2022009059A
- Authority
- MX
- Mexico
- Prior art keywords
- aurora
- heterocyclic compounds
- compounds useful
- selective inhibitors
- novel heterocyclic
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 239000005441 aurora Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen compuestos de fórmula (I) y sales farmacéuticamente aceptables de los mismos, que se pueden usar para inhibir la actividad de Aurora A y tratar el cáncer mediado por Aurora A (ver Fórmula).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020073786 | 2020-01-22 | ||
CN2020076159 | 2020-02-21 | ||
CN2020085922 | 2020-04-21 | ||
PCT/CN2021/073169 WO2021147974A1 (en) | 2020-01-22 | 2021-01-22 | Novel heterocyclic compounds useful as aurora a selective inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009059A true MX2022009059A (es) | 2022-08-15 |
Family
ID=76993163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009059A MX2022009059A (es) | 2020-01-22 | 2021-01-22 | Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20230128198A1 (es) |
EP (1) | EP4093736A4 (es) |
JP (1) | JP2023513419A (es) |
KR (1) | KR20220131514A (es) |
CN (2) | CN114423751B (es) |
AU (1) | AU2021209744B2 (es) |
CA (1) | CA3161268A1 (es) |
CL (1) | CL2022001951A1 (es) |
CO (1) | CO2022010878A2 (es) |
IL (1) | IL294247A (es) |
MX (1) | MX2022009059A (es) |
TW (1) | TWI785474B (es) |
WO (1) | WO2021147974A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112239465A (zh) * | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
AU2023224519A1 (en) * | 2022-02-23 | 2024-10-03 | Repare Therapeutics Inc. | Polo-like kinase 4 (plk4) inhibitors, pharmaceutical compositions, methods of preparation and uses thereof |
CN115057811B (zh) * | 2022-05-26 | 2024-06-14 | 安庆朗坤药业有限公司 | 一种2-溴甲基-3,5-二氟吡啶的制备方法 |
CN115322143B (zh) * | 2022-07-21 | 2023-07-14 | 安徽德诺医药股份有限公司 | 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法 |
CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008081492A (ja) * | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
US8519136B2 (en) * | 2008-02-22 | 2013-08-27 | Msd K.K. | Aminopyridine derivatives having aurora a selective inhibitory action |
TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
TWI693218B (zh) * | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光a激酶抑制劑 |
EA202191051A1 (ru) * | 2018-11-30 | 2021-08-26 | Эли Лилли Энд Компани | Ингибитор аврора-киназы a для применения для лечения нейробластомы |
CN112239465A (zh) * | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
-
2021
- 2021-01-21 TW TW110102296A patent/TWI785474B/zh active
- 2021-01-22 EP EP21743926.4A patent/EP4093736A4/en active Pending
- 2021-01-22 AU AU2021209744A patent/AU2021209744B2/en active Active
- 2021-01-22 MX MX2022009059A patent/MX2022009059A/es unknown
- 2021-01-22 JP JP2022544153A patent/JP2023513419A/ja active Pending
- 2021-01-22 KR KR1020227021336A patent/KR20220131514A/ko active Search and Examination
- 2021-01-22 US US17/794,641 patent/US20230128198A1/en active Pending
- 2021-01-22 CN CN202180003823.8A patent/CN114423751B/zh active Active
- 2021-01-22 CN CN202310353468.8A patent/CN116354936A/zh active Pending
- 2021-01-22 IL IL294247A patent/IL294247A/en unknown
- 2021-01-22 WO PCT/CN2021/073169 patent/WO2021147974A1/en active Application Filing
- 2021-01-22 CA CA3161268A patent/CA3161268A1/en active Pending
- 2021-09-24 US US17/484,456 patent/US11384066B1/en active Active
-
2022
- 2022-07-19 CL CL2022001951A patent/CL2022001951A1/es unknown
- 2022-08-02 CO CONC2022/0010878A patent/CO2022010878A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202140449A (zh) | 2021-11-01 |
KR20220131514A (ko) | 2022-09-28 |
AU2021209744A1 (en) | 2022-07-07 |
CL2022001951A1 (es) | 2023-04-14 |
CA3161268A1 (en) | 2021-07-29 |
CO2022010878A2 (es) | 2022-08-19 |
WO2021147974A1 (en) | 2021-07-29 |
US11384066B1 (en) | 2022-07-12 |
US20230128198A1 (en) | 2023-04-27 |
JP2023513419A (ja) | 2023-03-31 |
EP4093736A4 (en) | 2024-01-10 |
CN114423751A (zh) | 2022-04-29 |
CN116354936A (zh) | 2023-06-30 |
AU2021209744B2 (en) | 2023-08-31 |
CN114423751B (zh) | 2023-04-21 |
TWI785474B (zh) | 2022-12-01 |
EP4093736A1 (en) | 2022-11-30 |
IL294247A (en) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009059A (es) | Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a. | |
SA522432955B1 (ar) | Kras g12c مثبطات | |
PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
MX2023000025A (es) | Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos. | |
PH12017501326A1 (en) | Tgf-� inhibitors | |
MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
MX2024001824A (es) | Compuestos heterociclicos y metodos de uso. | |
MX2021013531A (es) | Inhibidores de cdk. | |
MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
MX2021006695A (es) | Moduladores de trex1. | |
EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
CR20230598A (es) | Inhibidores de cdk2 | |
MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
MX2019006843A (es) | Inhibidor de cdk4/6. | |
MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
MX2023015245A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2. | |
MX2021008136A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met. | |
MX2021001804A (es) | Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. |